US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neo-Concept International Group Holdings Limited

1.92

+0.680054.84%

Post-market: 1.64-0.2800-14.58%19:59 EST

Volume:34.07M

Turnover:63.86M

Market Cap:7.80M

PE:7.05

High:1.92

Open:1.66

Low:1.47

Close:1.24

52wk High:8.15

52wk Low:0.9000

Shares:4.06M

Float Shares:945.20K

Volume Ratio:60.38

T/O Rate:3604.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2723

EPS(LYR):0.2648

ROE:16.08%

ROA:6.19%

PB:1.04

PE(LYR):7.25

Loading ...

Overview Company News Filings

Press Release: SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Neo-Concept International H1 EPS $0.06 Up From $0.05 YoY, Sales $7.674M Down From $10.150M YoY

Press Release: Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

The Market Doesn't Like What It Sees From Neo-Concept International Group Holdings Limited's (NASDAQ:NCI) Earnings Yet

Simply Wall St.

New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Shell announces commencement of a share buyback programme

Press Release: Shell plc Third Quarter 2025 Interim Dividend

Shell plc publishes third quarter 2025 press release

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":1.92,"timestamp":1765573200000,"preClose":1.24,"halted":0,"volume":34073101,"hourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.92,"latestTime":"19:59 EST","volume":2368228,"amount":4561407.3924,"timestamp":1765587596200},"delay":0,"floatShares":945200,"shares":4064000,"eps":0.272333,"marketStatus":"Market Closed","change":0.68,"latestTime":"12-12 16:00:00 EST","open":1.66,"high":1.92,"low":1.47,"amount":63860562.3170422,"amplitude":0.362903,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.272333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.66,"preClose":1.24,"latestTime":"09:29 EST","volume":5632218,"amount":10594375.5303144,"timestamp":1765549799999},"postHourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.92,"latestTime":"19:59 EST","volume":2368228,"amount":4561407.3924,"timestamp":1765587596200},"volumeRatio":60.37851019122318},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":945200,"roa":"6.19%","roe":"16.08%","lyrEps":0.264768,"volumeRatio":60.37851019122318,"shares":4064000,"dividePrice":0,"high":1.92,"amplitude":0.362903,"preClose":1.24,"low":1.47,"week52Low":0.9,"pbRate":"1.04","psRate":"0.28","week52High":8.15,"institutionHeld":0.7857,"latestPrice":1.92,"eps":0.272333,"divideRate":0,"volume":34073101,"delay":0,"ttmEps":0.272333,"open":1.66,"prevYearClose":3.3,"prevWeekClose":1.15,"prevMonthClose":1.17,"prevQuarterClose":1.83,"fiveDayClose":1.15,"twentyDayClose":1.07,"sixtyDayClose":1.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-16","symbol":"NCI","defaultRemindTime":1750080600000,"type":"split","dateTimestamp":1750046400000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-12-12","current":7.050192,"percent":0.09466,"low":-615.963293,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"high":50.092968,"avg":7.676551,"sd":39.888864,"marketCap":5039382},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":25.951993,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":14650720},{"date":"2024-06-07","current":26.211896,"twenty":-81.702314,"median":25.015338,"eighty":34.642796,"marketCap":14813280},{"date":"2024-06-14","current":29.519581,"twenty":-78.809845,"median":25.103888,"eighty":32.998302,"marketCap":16682720},{"date":"2024-06-21","current":25.962557,"twenty":-75.44284,"median":25.889128,"eighty":31.491027,"marketCap":14685264},{"date":"2024-06-28","current":22.645555,"twenty":-74.134092,"median":25.192438,"eighty":30.05782,"marketCap":12803632},{"date":"2024-07-05","current":22.365126,"twenty":-73.07826,"median":25.015338,"eighty":29.519581,"marketCap":12639040},{"date":"2024-07-12","current":23.313894,"twenty":-71.810291,"median":24.273321,"eighty":28.980357,"marketCap":13183616},{"date":"2024-07-19","current":21.771249,"twenty":-70.527871,"median":24.005484,"eighty":28.783514,"marketCap":12305792},{"date":"2024-07-26","current":19.871565,"twenty":-67.981499,"median":23.548157,"eighty":28.579978,"marketCap":11236980},{"date":"2024-08-02","current":17.380948,"twenty":-63.611082,"median":23.313894,"eighty":28.402846,"marketCap":9828784},{"date":"2024-08-09","current":14.824233,"twenty":14.824233,"median":22.666232,"eighty":28.339976,"marketCap":8393176},{"date":"2024-08-16","current":14.891311,"twenty":14.824233,"median":22.428658,"eighty":26.393551,"marketCap":8432800},{"date":"2024-08-23","current":16.505019,"twenty":14.824233,"median":21.843651,"eighty":26.38192,"marketCap":9347200},{"date":"2024-08-30","current":15.221442,"twenty":14.891311,"median":21.615595,"eighty":26.235018,"marketCap":8617712},{"date":"2024-09-06","current":14.786956,"twenty":14.816778,"median":21.03365,"eighty":26.21652,"marketCap":8375904},{"date":"2024-09-13","current":18.291286,"twenty":14.783803,"median":19.997266,"eighty":26.012425,"marketCap":10355072},{"date":"2024-09-20","current":25.287335,"twenty":14.816778,"median":19.871565,"eighty":26.012425,"marketCap":14325600},{"date":"2024-09-27","current":18.961375,"twenty":14.877895,"median":19.084343,"eighty":25.954106,"marketCap":10769600},{"date":"2024-10-04","current":21.913118,"twenty":15.042266,"median":20.067523,"eighty":26.126798,"marketCap":12454128},{"date":"2024-10-11","current":22.176748,"twenty":15.165199,"median":20.049509,"eighty":25.99115,"marketCap":12598400},{"date":"2024-10-18","current":32.898839,"twenty":15.206634,"median":20.803771,"eighty":26.126798,"marketCap":18694400},{"date":"2024-10-25","current":23.358148,"twenty":15.219487,"median":21.352319,"eighty":26.21652,"marketCap":13270992},{"date":"2024-11-01","current":27.487373,"twenty":15.232907,"median":21.771249,"eighty":26.583872,"marketCap":15603728},{"date":"2024-11-08","current":26.826792,"twenty":15.38624,"median":21.882165,"eighty":26.827702,"marketCap":15231872},{"date":"2024-11-15","current":22.217928,"twenty":15.464941,"median":22.207911,"eighty":26.517352,"marketCap":12598400},{"date":"2024-11-22","current":19.532206,"twenty":15.526206,"median":22.192329,"eighty":26.402839,"marketCap":11076432},{"date":"2024-11-29","current":19.712189,"twenty":15.580772,"median":21.882165,"eighty":26.386572,"marketCap":11184128},{"date":"2024-12-06","current":18.691913,"twenty":15.639248,"median":21.771249,"eighty":26.293779,"marketCap":10607040},{"date":"2024-12-13","current":18.611126,"twenty":15.691094,"median":21.352319,"eighty":26.221145,"marketCap":10566400},{"date":"2024-12-20","current":7.102414,"twenty":15.639248,"median":20.803771,"eighty":26.151136,"marketCap":10058400},{"date":"2024-12-27","current":7.471029,"twenty":15.444399,"median":20.742686,"eighty":26.108587,"marketCap":10592816},{"date":"2025-01-03","current":10.196837,"twenty":15.213623,"median":20.067523,"eighty":26.07693,"marketCap":14427200},{"date":"2025-01-10","current":10.034934,"twenty":14.891311,"median":20.043836,"eighty":25.962557,"marketCap":14183360},{"date":"2025-01-17","current":9.907617,"twenty":14.749465,"median":19.895277,"eighty":25.951993,"marketCap":14008608},{"date":"2025-01-24","current":9.563114,"twenty":13.631492,"median":19.697706,"eighty":25.85141,"marketCap":13512800},{"date":"2025-01-31","current":8.48834,"twenty":10.018271,"median":19.532206,"eighty":25.746589,"marketCap":11988800},{"date":"2025-02-07","current":7.730432,"twenty":9.882149,"median":19.361654,"eighty":25.46422,"marketCap":10919968},{"date":"2025-02-14","current":7.130829,"twenty":9.483748,"median":19.090069,"eighty":25.309589,"marketCap":10081768},{"date":"2025-02-21","current":7.314786,"twenty":8.865676,"median":18.969464,"eighty":25.26403,"marketCap":10361168},{"date":"2025-02-28","current":5.889209,"twenty":8.594149,"median":18.858804,"eighty":25.21486,"marketCap":8333232},{"date":"2025-03-07","current":6.028973,"twenty":8.100004,"median":18.691913,"eighty":25.173677,"marketCap":8536432},{"date":"2025-03-14","current":5.598897,"twenty":7.846255,"median":18.496802,"eighty":25.10156,"marketCap":7926832},{"date":"2025-03-21","current":5.968988,"twenty":7.540872,"median":18.291286,"eighty":25.033931,"marketCap":8451088},{"date":"2025-03-28","current":7.03753,"twenty":7.389256,"median":18.105135,"eighty":24.856699,"marketCap":9956800},{"date":"2025-04-04","current":6.201809,"twenty":7.119463,"median":17.654152,"eighty":24.701604,"marketCap":8778240},{"date":"2025-04-11","current":6.159082,"twenty":7.009081,"median":17.557752,"eighty":24.560727,"marketCap":8737600},{"date":"2025-04-17","current":6.305413,"twenty":6.892251,"median":17.348506,"eighty":24.472151,"marketCap":8938768},{"date":"2025-04-25","current":5.299322,"twenty":6.518915,"median":16.836333,"eighty":24.40328,"marketCap":7518400},{"date":"2025-05-02","current":4.437465,"twenty":6.31653,"median":16.510738,"eighty":24.325687,"marketCap":6301232},{"date":"2025-05-09","current":5.171449,"twenty":6.285391,"median":16.156269,"eighty":24.224718,"marketCap":7317232},{"date":"2025-05-16","current":6.695699,"twenty":6.181855,"median":15.685852,"eighty":24.063819,"marketCap":6908800},{"date":"2025-05-23","current":7.021962,"twenty":6.235146,"median":15.538955,"eighty":24.008491,"marketCap":7233920},{"date":"2025-05-30","current":8.164705,"twenty":6.285272,"median":15.423857,"eighty":24.005032,"marketCap":8397532},{"date":"2025-06-06","current":8.847265,"twenty":6.289683,"median":15.216555,"eighty":23.931629,"marketCap":9092468},{"date":"2025-06-13","current":8.179292,"twenty":6.306628,"median":15.080005,"eighty":23.644242,"marketCap":8402196},{"date":"2025-06-20","current":10.670242,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"marketCap":10960400},{"date":"2025-06-27","current":11.716334,"twenty":6.315883,"median":14.760327,"eighty":23.456094,"marketCap":12034985},{"date":"2025-07-03","current":10.216346,"twenty":6.317177,"median":14.71349,"eighty":23.384943,"marketCap":10494000},{"date":"2025-07-11","current":10.261711,"twenty":6.410478,"median":11.716334,"eighty":23.359949,"marketCap":10540640},{"date":"2025-07-18","current":9.808428,"twenty":6.454657,"median":10.875077,"eighty":23.322745,"marketCap":10077038},{"date":"2025-07-25","current":9.671429,"twenty":6.462794,"median":10.624987,"eighty":23.130117,"marketCap":9934320},{"date":"2025-08-01","current":8.89955,"twenty":6.57431,"median":10.442049,"eighty":23.054884,"marketCap":9141440},{"date":"2025-08-08","current":8.26371,"twenty":6.676961,"median":10.261711,"eighty":22.850835,"marketCap":8488480},{"date":"2025-08-15","current":8.020396,"twenty":6.711807,"median":10.206559,"eighty":22.709857,"marketCap":8255280},{"date":"2025-08-22","current":7.944228,"twenty":6.718226,"median":10.054926,"eighty":22.653826,"marketCap":8198379},{"date":"2025-08-29","current":7.484931,"twenty":6.73937,"median":9.97069,"eighty":22.584141,"marketCap":7742240},{"date":"2025-09-05","current":9.159836,"twenty":6.821347,"median":9.934593,"eighty":22.562922,"marketCap":9467920},{"date":"2025-09-12","current":9.23611,"twenty":6.883125,"median":9.907617,"eighty":22.500907,"marketCap":9561200},{"date":"2025-09-19","current":8.862273,"twenty":6.893296,"median":9.771265,"eighty":22.442063,"marketCap":9188080},{"date":"2025-09-26","current":7.431141,"twenty":6.901678,"median":9.711704,"eighty":22.390539,"marketCap":7701314},{"date":"2025-10-03","current":7.413811,"twenty":6.942194,"median":9.659792,"eighty":22.276807,"marketCap":7680994},{"date":"2025-10-10","current":7.489961,"twenty":6.99974,"median":9.578721,"eighty":22.211918,"marketCap":7762274},{"date":"2025-10-17","current":7.128574,"twenty":6.974212,"median":9.51173,"eighty":22.189213,"marketCap":7396512},{"date":"2025-10-24","current":6.854291,"twenty":6.883125,"median":9.462569,"eighty":22.01857,"marketCap":7112031},{"date":"2025-10-31","current":6.186973,"twenty":6.854004,"median":9.33225,"eighty":21.875975,"marketCap":6421148},{"date":"2025-11-07","current":4.741629,"twenty":6.765339,"median":9.223624,"eighty":21.842138,"marketCap":4917461},{"date":"2025-11-14","current":4.19042,"twenty":6.696493,"median":9.126243,"eighty":21.797185,"marketCap":4348499},{"date":"2025-11-21","current":3.92273,"twenty":6.462068,"median":9.081059,"eighty":21.677857,"marketCap":4064018},{"date":"2025-11-28","current":4.258196,"twenty":6.343606,"median":9.054357,"eighty":21.613946,"marketCap":4754901},{"date":"2025-12-05","current":4.259674,"twenty":6.293615,"median":8.88422,"eighty":21.40415,"marketCap":4754901},{"date":"2025-12-12","current":4.514242,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"marketCap":5039382}],"updateTime":1765623824272},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589382559","title":"Press Release: SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2589382559","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589382559?lang=en_us&edition=fundamental","pubTime":"2025-12-08 15:00","pubTimestamp":1765177200,"startTime":"0","endTime":"0","summary":"The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2025 interim dividend, which was announced on October 30, 2025 at US$0.358 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by November 28, 2025 will be entitled to a dividend of US$0.358, EUR0.3070 or 26.85p per ordinary share, respectively.Euro and pounds sterling dividends payable in cash have been converted from US dollars based on an average of market exchange rates over the three dealing days from December 3 to December 5, 2025. This dividend will be payable on December 18, 2025 to those members whose names were on the Register of Members on November 14, 2025.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","BK4588","LU0300736062.USD","LU0300736492.USD","BK4201","LU0278409577.USD","NCI","LU0320765646.SGD","LU2236285917.USD","LU0098860793.USD","BK4202","BK4585","SHEL"],"gpt_icon":0},{"id":"2588881197","title":"Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881197","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881197?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:30","pubTimestamp":1764851400,"startTime":"0","endTime":"0","summary":"Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199678/0/en/Plus-Therapeutics-Highlights-Three-REYOBIQ-Clinical-Data-Presentations-at-2025-WFNOS-SNO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CNS","NCI","BK4539","BK4007","BK4202","BK4135","BK4139"],"gpt_icon":0},{"id":"2588727632","title":"Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727632","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727632?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Study findings to be featured in a poster spotlight presentationHOUSTON, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical comp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196910/0/en/Plus-Therapeutics-to-Present-ReSPECT-Phase-1-Dose-Escalation-Study-Results-for-Leptomeningeal-Metastases-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","LENZ","CNS","BK4139","BK4135","BK4007","BK4202","BK4539"],"gpt_icon":0},{"id":"2585643714","title":"Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2585643714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585643714?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987400,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193399/0/en/Plus-Therapeutics-Announces-Completion-of-U-S-FDA-Meeting-on-Future-Clinical-Development-Plans-for-REYOBIQ-in-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135","LENZ","NCI","BK4139","BK4202","BK4007","BK4539"],"gpt_icon":0},{"id":"2585141798","title":"Neo-Concept International H1 EPS $0.06 Up From $0.05 YoY, Sales $7.674M Down From $10.150M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141798","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585141798?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:12","pubTimestamp":1763737971,"startTime":"0","endTime":"0","summary":"Neo-Concept International (NASDAQ:NCI) reported quarterly earnings of $0.06 per share. This is a 20 percent increase over earnings of $0.05 per share from the same period last year.  The company reported $7.674 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/49003998/neo-concept-international-h1-eps-0-06-up-from-0-05-yoy-sales-7-674m-down-from-10-150m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","NQmain","NVIW.SI","USJW.SI","QID","SQQQ","BK4202","TQQQ","MNQmain","USAW.SI","QLD","PSQ",".IXIC","TSYW.SI"],"gpt_icon":0},{"id":"2585149782","title":"Press Release: Neo-Concept International Group Holdings Limited Announces First Half 2025 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149782","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585149782?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:40","pubTimestamp":1763736000,"startTime":"0","endTime":"0","summary":"Hong Kong, Nov. 21, 2025  -- Neo-Concept International Group Holdings Limited  , today announced its unaudited financial results for the six months ended June 30, 2025.-- Revenue was approximately HK$60.2 million  for the six. months ended June 30, 2025, representing a decrease of approximately. -- Net income was approximately HK$2.0 million  for the six. months ended June 30, 2025 (2024: net income approximately HK$1.4. Other income, net. Other income representing agency fee received decreased approximately 47.1% from HK$2.4 million for the six months ended June 30, 2024 to HK$1.2 million  for the six months ended June 30, 2025, the agency fee represents for liaison with customers of the related party based in United Kingdom including making price quotation, handling purchase order, after-sales service, etc. The primary reason for the decrease was a decline in sales activity of the related party in United Kingdom, which adversely impacted the agency fee.Income tax expense. Income tax ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2585987481","title":"National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2585987481","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585987481?lang=en_us&edition=fundamental","pubTime":"2025-11-21 11:19","pubTimestamp":1763695140,"startTime":"0","endTime":"0","summary":"The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving medicines for patients. About MedidataMedidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand , Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest pod","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2699901/Medidata_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2699901/Medidata_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/national-cancer-institute-broadens-partnership-with-medidata-to-bring-unmatched-continuity-of-medical-and-clinical-data-for-lead-protocol-organizations-302622705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","NHLD","BK4202"],"gpt_icon":0},{"id":"2583567674","title":"Press Release: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567674","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567674?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Phase 2 Results Lead Company to Seek Expedited Approval Pathway in Ongoing. Conference Call and Webcast today at 8:00 a.m. Eastern Time. PRINCETON, N.J., Nov. 13, 2025  -- PDS Biotechnology Corporation  , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical programs update.\"Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the encouraging data from our now completed VERSATILE-002 trial\", said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. \"We believe the positive PFS data offers an important opportunity to shorten the trial duration and time to regulatory submission while maintaining mOS as the endpoint for full FDA approval. Importantly, we believe this approach may also accelerate the availab","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4099","ADC","SITC","BK4604","BK4585","BK4139","BK4588","BK4080","BK4232","BK4555","BK4202","BK4022","BK4231","PDS","BK4092","NCI","TM","03160","PDSB"],"gpt_icon":0},{"id":"2582391872","title":"PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582391872","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582391872?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:30","pubTimestamp":1762781400,"startTime":"0","endTime":"0","summary":"Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapyPDS01ADC reprograms natural killer (NK) cells to possess characteristics th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184578/37149/en/PDS-Biotechnology-Announces-Translational-Data-Showing-Strong-Immunological-and-Clinical-Activity-of-PDS0101-and-PDS01ADC-Presented-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU1989771016.USD","SG9999014567.USD","LU0861579265.USD","LU0265550946.USD","LU2361045086.USD","LU2112291526.USD","SG9999002224.SGD","LU1066051811.HKD","LU1974910355.USD","LU2023250843.SGD","SG9999015341.SGD","SGXZ57979304.SGD","LU1917777945.USD","LU0320765646.SGD","LU0211331839.USD","ADC","IE00BLSP4452.SGD","BK4550","LU2361044865.SGD","BK4533","IE000M9KFDE8.USD","LU1699723380.USD","BK4559","PDS","LU0234572021.USD","IE00BFTCPJ56.SGD","IE0003851619.USD","SITC","LU0208291251.USD","SG9999015358.SGD","BK4092","IE00B2B36J28.USD","LU1023059063.AUD","LU1069347547.HKD","LU1430594728.SGD","BK4588","LU1929549753.HKD","CCR","SG9999014542.SGD","BK4534","LU1934455863.HKD","MRK","LU2361044949.HKD","BK4202","IE00BYQNZ168.SGD","SG9999002232.USD","01308","NCI"],"gpt_icon":0},{"id":"2581266888","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581266888","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581266888?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:01","pubTimestamp":1762520460,"startTime":"0","endTime":"0","summary":"-- The net result as of September 30, 2025 improved by $1.1M compared to. September 2024, following termination of a Convertible Bonds financing. --    Received feedback from the FDA on Phase III PORTICO-2        --    Positive data in 1L AML to be presented at ASH with. trial in BPD; Company to revise protocol and resubmit                               100% ORR . --    Reinforcing company's clinical, strategy and              --    Positive data in R/R FLT3+ AML to be presented at. \"We have secured over $60 million in the first half of 2025, marking a significant turnaround for Oryzon,\" said Dr. Carlos Buesa, Oryzon's Chief Executive Officer. \"These proceeds enable us to advance our clinical programs with a renewed strategic focus on CNS, particularly in our studies in BPD, schizophrenia, and ASD.\". \"Following the FDA's feedback, the Company has strengthened its clinical, strategic, and regulatory teams by incorporating highly experienced professionals with deep expertise in late-stag","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","ORR","BK4097","BK4109","OS","NCI","BK4161","ASH","LU2463526074.USD","BK4202"],"gpt_icon":0},{"id":"2581888267","title":"BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888267","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888267?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518600,"startTime":"0","endTime":"0","summary":"Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183561/0/en/BriaCell-Presents-Robust-Anti-Cancer-Activity-of-Bria-OTS-at-SITC-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","IE00BYQNZ168.SGD","IE00B12V2V27.USD","NCI","SG9999011746.SGD","BCTX","BK4139","BK4231","SITC","01308","IE00BYTNYN87.SGD","IE0003851619.USD","BK1103","BK4202","BK1541","IE0003795394.USD"],"gpt_icon":0},{"id":"2581100734","title":"Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2581100734","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581100734?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516800,"startTime":"0","endTime":"0","summary":"Data from studies conducted by investigators at the National Cancer Institute at NCI laboratories, part of a multi-year research effort, will be presented at SITCDover, DE, Nov.  07, 2025  (GLOBE NEWS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183521/0/en/Complete-Tumor-Regressions-Observed-in-Preclinical-Models-with-Co-administration-of-Cyncado-s-A2B-and-A2A-Receptor-Antagonists-and-Cancer-Vaccines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2581954740","title":"Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2581954740","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581954740?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432200,"startTime":"0","endTime":"0","summary":"Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ and ReSPECT-LM, and future directions and needsHOUSTON, Nov.  06, 2025  (GLOBE NEWSWIRE) -- Plus Therapeutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182450/0/en/Plus-Therapeutics-Highlights-ReSPECT-LM-Clinical-Trial-Results-at-40th-SITC-Annual-Meeting-Melanoma-Research-Foundation-Brain-Metastases-Summit-4-0.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0003851619.USD","BK4231","NCI","01308","CNS","BK4539","BK4211","SITC","IE00B12V2V27.USD","BK1103","BK4202","BK4135","IE00BYQNZ168.SGD","IE00BYTNYN87.SGD","BK1541","BK4007","LENZ","BK4080","BK4139","IE0003795394.USD","SG9999011746.SGD","SMMF"],"gpt_icon":0},{"id":"2580739996","title":"BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739996","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739996?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:30","pubTimestamp":1762259400,"startTime":"0","endTime":"0","summary":"SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180205/0/en/BriaCell-to-Present-Robust-Anti-Cancer-Activity-of-Bria-OTS-in-Breast-and-Prostate-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4231","NCI","BK4202","SITC","BK4080","BCTX"],"gpt_icon":0},{"id":"2580478885","title":"The Market Doesn't Like What It Sees From Neo-Concept International Group Holdings Limited's (NASDAQ:NCI) Earnings Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478885","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580478885?lang=en_us&edition=fundamental","pubTime":"2025-11-01 20:49","pubTimestamp":1762001396,"startTime":"0","endTime":"0","summary":"When close to half the companies in the United States have price-to-earnings ratios (or \"P/E's\") above 19x, you may...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4131000-choice2-main-header/1585186733037","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4131000-choice2-main-header/1585186733037"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-durables/nasdaq-nci/neo-concept-international-group-holdings/news/the-market-doesnt-like-what-it-sees-from-neo-concept-interna","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nasdaq-nci/neo-concept-international-group-holdings/news/the-market-doesnt-like-what-it-sees-from-neo-concept-interna","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NCI","01336",".IXIC"],"gpt_icon":0},{"id":"2579494221","title":"New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579494221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579494221?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825600,"startTime":"0","endTime":"0","summary":"Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy plat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177312/37149/en/New-Clinical-and-Translational-Data-on-PDS-Biotechnology-s-Novel-Investigational-Cancer-Therapies-PDS0101-and-PDS01ADC-to-be-Presented-at-the-2025-Society-for-Immunotherapy-of-Canc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDS","SITC","BK4092","BK4231","BK1103","NCI","01308","BK4202","ADC","IE00BYQNZ168.SGD","IE00BYTNYN87.SGD","IE00B12V2V27.USD","SG9999011746.SGD","BK4080","BK1541"],"gpt_icon":0},{"id":"2579193294","title":"Shell announces commencement of a share buyback programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2579193294","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579193294?lang=en_us&edition=fundamental","pubTime":"2025-10-30 15:03","pubTimestamp":1761807780,"startTime":"0","endTime":"0","summary":"Shell plc   Shell announces commencement of a share buyback programme October 30, 2025 Shell plc (the ‘Company’) today announces the commencement of a $3.5 billion share buyback programme covering an ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177087/0/en/Shell-announces-commencement-of-a-share-buyback-programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","NCI","BK4202"],"gpt_icon":0},{"id":"2579724193","title":"Press Release: Shell plc Third Quarter 2025 Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2579724193","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579724193?lang=en_us&edition=fundamental","pubTime":"2025-10-30 15:02","pubTimestamp":1761807720,"startTime":"0","endTime":"0","summary":"London, October 30, 2025 - The Board of Shell plc   today announced an interim dividend in respect of the third quarter of 2025 of US$ 0.358 per ordinary share.Details relating to the third quarter 2025 interim dividend. Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling.An alternative 'Electronic Election Entitlement'  process is available in CREST for dividends with options elections.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt  certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the third quarter 2025 interim dividend. The fo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0278409577.USD","BK4202","BK4588","LU0300736492.USD","NCI","BK4201","SHEL","LU2236285917.USD","LU0320765646.SGD","LU0300736062.USD","BK4585","LU0098860793.USD","LU1162221912.USD"],"gpt_icon":0},{"id":"2579819326","title":"Shell plc publishes third quarter 2025 press release","url":"https://stock-news.laohu8.com/highlight/detail?id=2579819326","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579819326?lang=en_us&edition=fundamental","pubTime":"2025-10-30 15:01","pubTimestamp":1761807660,"startTime":"0","endTime":"0","summary":"London, October 30, 2025 \"Shell delivered another strong set of results, with clear progress across our portfolio and excellent performance in our Marketing business and deepwater assets in the Gulf o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177083/0/en/Shell-plc-publishes-third-quarter-2025-press-release.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","BK4561","BK4006","MT"],"gpt_icon":0},{"id":"2578288966","title":"MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578288966","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578288966?lang=en_us&edition=fundamental","pubTime":"2025-10-27 22:45","pubTimestamp":1761576300,"startTime":"0","endTime":"0","summary":"First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct.  27, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174761/0/en/MAIA-Biotechnology-Presents-Trial-in-Progress-Poster-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","NCI","BK4097","BK1584","LU0572939691.SGD","LU2487616109.SGD","ORR","01336","MAIA","BK4139","LU0210528500.USD","NIC","L","BK4585","BK4588","PRGS","BK4007","BK1184","BK1550","LU2065732104.USD","LU0572940350.SGD","BK4539","BK4211","LU0053666078.USD","CPI","BK4107","LENZ","BK4202"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}]}}